Ignite Creation Date:
2024-05-06 @ 2:28 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02057692
Status:
COMPLETED
Last Update Posted:
2019-03-26
First Post:
2014-02-05
Brief Title:
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
Sponsor:
Mirum Pharmaceuticals Inc
Organization:
Mirum Pharmaceuticals Inc
Study Overview
Official Title:
The Evaluation of the Intestinal Bile Acid Transport IBAT Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome a Cholestatic Liver Disease
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ITCH
Brief Summary:
The study is a randomized double-blind placebo-controlled study in children with Alagille Syndrome ALGS The study will investigate the effects of LUM001 compared to placebo on pruritus serum bile acids liver enzymes and other biochemical markers in patients with ALGS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None